GERN - NASDAQ

Geron Corporation

GERN·NASDAQ

$1.16

-0.85%

HealthcareBiotechnology

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$744.16M

EPS-0.1300

P/E Ratio-8.92

Earnings Date08/05/2026

gern

Cash and Short Term Investments

Last Annual Value

359.80M

3-Year CAGR

28%

5-Year CAGR

13%

10-Year CAGR

12%

Adjust for Inflation

Geron Corporation Competitors Analysis of Cash and Short Term Investments

GERN · NASDAQ

Company	Cash and Short Term Investments	CAGR 3Y	CAGR 5Y	CAGR 10Y
Geron Corporation NASDAQ:GERN	359.80M	2.5%	14.4%	12.1%
Tyra Biosciences, Inc. NASDAQ:TYRA	256.00M	8.0%	-3.3%	N/A
Vir Biotechnology, Inc. NASDAQ:VIR	462.86M	-32.8%	-8.2%	N/A
Arvinas, Inc. NASDAQ:ARVN	685.40M	-18.4%	-14.5%	34.4%
Rezolute, Inc. NASDAQ:RZLT	167.86M	18.1%	32.5%	45.1%
Day One Biopharmaceuticals, Inc. NASDAQ:DAWN	441.11M	6.4%	9.2%	N/A
Savara Inc. NASDAQ:SVRA	235.70M	13.2%	7.9%	33.2%
Replimune Group, Inc. NASDAQ:REPL	483.80M	-6.0%	0.3%	N/A
LENZ Therapeutics, Inc. NASDAQ:LENZ	292.35M	64.4%	74.0%	N/A
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP	312.82M	27.7%	53.0%	N/A

Geron Corporation Fair Value Envelope

GERN · NASDAQ

Our analysis suggests that GERN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.16, this represents a potential HIDDEN relative to our calculated worth for Geron Corporation.

HIDDEN

Intrinsic Value

Current Price: $1.16

Related Guides

Blog Categories

Continue your GERN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.